Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus - Report of 17 cases and review of the literature

Lupus

Volumn 22, Issue 9, 2013, Pages 932-939

  Hofmann, S C ^a,b   Leandro, M J ^a   Morris, S D ^c   Isenberg, D A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF WITTEN HERDECKE   (Germany)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Cutaneous lupus; discoid lupus; subacute lupus erythematosus; systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADULT; ADVERSE OUTCOME; B CELL DEPLETION THERAPY; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; MALE; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; REVIEW; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; B LYMPHOCYTE; COHORT ANALYSIS; FEMALE; FOLLOW UP; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, CUTANEOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; RECURRENT DISEASE;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, CUTANEOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 84880910638     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203313497115     Document Type: Review

References (30)

1. Rothfield N, Sontheimer RD, Bernstein M. Lupus erythematosus: Systemic and cutaneous manifestations. Clin Dermatol. 2006 ; 24: 348-362
2. Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012 ; 64: 2677-2686
3. Werth VP. Cutaneous lupus: Insights into pathogenesis and disease classification. Bull NYU Hosp Jt Dis. 2007 ; 65: 200-204
4. Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: Update of therapeutic options part I. J Am Acad Dermatol. 2011 ; 65: e179 - e193
5. Jessop S, Whitelaw DA, Delamere FM. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev. 2009 ;: CD002954 - CD002954
6. Borchers AT, Keen CL, Shoenfeld Y, Gershwin ME. Surviving the butterfly and the wolf: Mortality trends in systemic lupus erythematosus. Autoimmun Rev. 2004 ; 3: 423-453
7. Kind P, Lipsky PE, Sontheimer RD. Circulating T- and B-cell abnormalities in cutaneous lupus erythematosus. J Invest Dermatol. 1986 ; 86: 235-239
8. Batista FD, Harwood NE. The who, how and where of antigen presentation to B cells. Nat Rev Immunol. 2009 ; 9: 15-27
9. Lu TY, Ng KP, Cambridge G, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: The first fifty patients. Arthritis Rheum. 2009 ; 61: 482-487
10. Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA. Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. Lupus. 2009 ; 18: 767-776
11. Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 2010 ; 62: 2458-2466
12. Looney RJ. B cell-targeted therapies for systemic lupus erythematosus: An update on clinical trial data. Drugs. 2010 ; 70: 529-540
13. Merrill J, Buyon J, Furie R, et al. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus. 2011 ; 20: 709-716
14. Isenberg DA, Allen E, Farewell V, et al. An assessment of disease flare in patients with systemic lupus erythematosus: A comparison of BILAG 2004 and the flare version of SELENA. Ann Rheum Dis. 2011 ; 70: 54-59
15. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 ; 25: 1271-1277
16. Hertl M, Zillikens D, Borradori L, et al. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases [in English and German]. J Dtsch Dermatol Ges. 2008 ; 6: 366-373
17. Emer JJ, Claire W. Rituximab: A review of dermatological applications. J Clin Aesthet Dermatol. 2009 ; 2: 29-37
18. Risselada AP, Kallenberg CG. Therapy-resistent lupus skin disease successfully treated with rituximab. Rheumatology (Oxford). 2006 ; 45: 915-916
19. Uthman I, Taher A, Abbas O, Menassa J, Ghosn S. Successful treatment of refractory skin manifestations of systemic lupus erythematosus with rituximab: Report of a case. Dermatology. 2008 ; 216: 257-259
20. McArdle A, Baker JF. A case of "refractory" lupus erythematosus profundus responsive to rituximab [case report]. Clin Rheumatol. 2009 ; 28: 745-746
21. Kieu V, O'Brien T, Yap LM, et al. Refractory subacute cutaneous lupus erythematosus successfully treated with rituximab. Australas J Dermatol. 2009 ; 50: 202-206
22. Kok MR, Vos K, Bos JD, Tak PP. Remission of incapacitating acute cutaneous lupus erythematosus in a patient with systemic lupus erythematosus by B cell-depletive therapy. J Clin Rheumatol. 2010 ; 16: 345-345
23. Alsanafi S, Kovarik C, Mermelstein AL, Werth VP. Rituximab in the treatment of bullous systemic lupus erythematosus. J Clin Rheumatol. 2011 ; 17: 142-144
24. Cieza-Díaz DE, Avilés-Izquierdo JA, Ceballos- Rodríguez C, Suárez-Fernández R. Refractory subacute cutaneous lupus erythematosus treated with rituximab [in Spanish]. Actas Dermosifiliogr. 2012 ; 103: 555-557
25. Marks SD, Patey S, Brogan PA, et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum. 2005 ; 52: 3168-3174
26. Wenzel J, Zahn S, Tuting T. Pathogenesis of cutaneous lupus erythematosus: Common and different features in distinct subsets. Lupus. 2010 ; 19: 1020-1028
27. Cortés-Hernández J, Torres-Salido M, Castro-Marrero J, Vilardell-Tarres M, Ordi-Ros J. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: Prognostic factors of clinical outcome. Br J Dermatol. 2012 ; 166: 616-623
28. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010 ; 62: 222-233
29. Popa C, Leandro MJ, Cambridge G, Edwards JC. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford). 2007 ; 46: 626-630
30. Kuhn A, Meuth AM, Bein D, et al. Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): A modified outcome instrument for cutaneous lupus erythematosus. Br J Dermatol. 2010 ; 163: 83-92